Abstract

Most of the prescribing and dispensing of medicines happens in primary care. Pharmacogenomics (PGx) is the study and clinical application of the role of genetic variation on drug response. Mounting evidence suggests PGx can improve the safety and/or efficacy of several medications commonly prescribed in primary care. However, implementation of PGx has generally been limited to a relatively few academic hospital centres, with little adoption in primary care. Despite this, many primary healthcare providers are optimistic about the role of PGx in their future practice. The increasing prevalence of direct-to-consumer genetic testing and primary care PGx studies herald the plausible gradual introduction of PGx into primary care and highlight the changes needed for optimal translation. In this article, the potential utility of PGx in primary care will be explored and on-going barriers to implementation discussed. The evidence base of several drug-gene pairs relevant to primary care will be outlined with a focus on antidepressants, codeine and tramadol, statins, clopidogrel, warfarin, metoprolol and allopurinol. This review is intended to provide both a general introduction to PGx with a more in-depth overview of elements relevant to primary care.

Highlights

  • It is increasingly recognised that individuals respond differently to medications

  • 1), CYP4F2 and human leukocyte antigen (HLA)-B (8).the subsequent sections in this review provide an overview of the role PGx can play in primary care in the prescribing and monitoring of specific medications related to these genes

  • The majority of prescribing happens in primary care

Read more

Summary

Introduction

It is increasingly recognised that individuals respond differently to medications. In some cases, these differences in response can be clinically significant leading to failure of therapy or adverse drug reactions (ADRs). Genomic variation in genes that modulate a drug’s PD (e.g., its therapeutic on-target and off-target sites) can directly influence drug response In both cases, the altered drug response can attenuate a drug’s efficacy or worsen tolerability/safety (Figure 1). Genetic polymorphisms in a drug’s leading to reduced effectiveness or type A ADRs. Lastly, many small molecule drugs bind with therapeutic target can directly modulate drug response, leading to reduced effectiveness or type A varying affinities to unintended off-target molecules, both within and separate to the immune system. In addition to serious ADRs leading to hospitalisation, implicated in causing hospitalisation, PGx guideline recommendations are available, such as for it is known that poor drug tolerability (for example due to mild adverse events) is associated with warfarin, antiplatelet agents and opioid analgesics [4].

Design
Antidepressants
Opioid Analgesics
Statins
Clopidogrel
Warfarin
Metoprolol
Allopurinol
Recent
Findings
10. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call